Gene · 871
Papers3,090
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 3,090
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Bioinspired Astrocyte-Derived Coating Promotes the In Vitro Proliferation of Human Neural Stem Cells While Maintaining Their Stemness. | Biomimetics (Basel) | 2023 | 38132528 | PubTator, text mining | PubMed |
| LUM as a novel prognostic marker and its correlation with immune infiltration in gastric cancer: a study based on immunohistochemical analysis and bioinformatics. | BMC Gastroenterol | 2023 | 38129820 | PubTator, text mining | PubMed |
| Recent Advances on the Molecular Mechanism and Clinical Trials of Venous Thromboembolism. | J Inflamm Res | 2023 | 38111686 | PubTator, text mining | PubMed |
| Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease. | Stem Cell Res Ther | 2023 | 38111001 | PubTator, text mining | PubMed |
| Relationship between intrathrombotic appearance of HSP27 and HSP70 and thrombus ages in a murine model of deep vein thrombosis. | Sci Rep | 2023 | 38104135 | PubTator, text mining | PubMed |
| An FGFR2 mutation as the potential cause of a new phenotype including early-onset osteoporosis and bone fractures: a case report. | BMC Med Genomics | 2023 | 38098042 | PubTator, text mining | PubMed |
| Combinational Gene Therapy toward Cancer with Nanoplatform: Strategies and Principles. | ACS Mater Au | 2023 | 38089659 | PubTator, text mining | PubMed |
| Elovanoid-N34 modulates TXNRD1 key in protection against oxidative stress-related diseases. | Cell Death Dis | 2023 | 38086796 | PubTator, text mining | PubMed |
| miR-29c-3p represses the angiogenesis of esophageal squamous cell carcinoma by targeting SERPINH1 to regulate the Wnt signaling pathway. | Acta Cir Bras | 2023 | 38055382 | PubTator, text mining | PubMed |
| Progress in the clinical treatment of keloids. | Front Med (Lausanne) | 2023 | 38046417 | PubTator, text mining | PubMed |
| Mechanobiological Strategies to Augment Cancer Treatment. | ACS Omega | 2023 | 38024751 | PubTator, text mining | PubMed |
| Prospective therapeutics for intestinal and hepatic fibrosis. | Bioeng Transl Med | 2023 | 38023697 | PubTator, text mining | PubMed |
| Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches. | J Pharm Pharm Sci | 2023 | 38022905 | PubTator, text mining | PubMed |
| A genome-wide and candidate gene association study of preterm birth in Korean pregnant women. | PLoS One | 2023 | 38019868 | PubTator, text mining | PubMed |
| Phototherapy techniques for the management of musculoskeletal disorders: strategies and recent advances. | Biomater Res | 2023 | 38017585 | PubTator, text mining | PubMed |
| Role of Microenvironmental Components in Head and Neck Squamous Cell Carcinoma. | J Pers Med | 2023 | 38003931 | PubTator, text mining | PubMed |
| Interaction of TSG101 with the PTAP Motif in Distinct Locations of Gag Determines the Incorporation of HTLV-1 Env into the Retroviral Virion. | Int J Mol Sci | 2023 | 38003710 | PubTator, text mining | PubMed |
| Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta. | BMJ Open | 2023 | 37993151 | PubTator, text mining | PubMed |
| Loss of p53-DREAM-mediated repression of cell cycle genes as a driver of lymph node metastasis in head and neck cancer. | Genome Med | 2023 | 37978395 | PubTator, text mining | PubMed |
| Performance evaluation of Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test for different diagnostic situations. | Microbiol Spectr | 2023 | 37966220 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/871/papers?page=12